Asian Journal of Medical Principles and Clinical Practice

Volume 7, Issue 1, Page 268-278, 2024; Article no.AJMPCP.117298

The Chest Radiographic Findings and the Viral Load in Adult Patients with HIV/PTB Co-Infection

Uzukwu Ifeanyi Olisa [a], Nwosu, Chinekwu Skye [a*], Nwabunike Munachi Onyebuchi [a], Isiakpu Idorenyin Okon [a] and Obi-Nwosu Amaka Lovelyn [b]

[a] Department of Radiology, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria.
[b] Department of Family Medicine Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

Open Peer Review History:
This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/117298

Original Research Article

Received: 14/03/2024
Accepted: 19/05/2024
Published: 23/05/2024

ABSTRACT

Introduction: The human immunodeficiency virus (HIV) infection continues to modify the radiographic pattern of pulmonary tuberculosis (PTB). There is an increase in the prevalence and transmission of multidrug-resistant and drug-resistant MTB strains worldwide.
Aim: To determine the relationship between the chest radiographic findings of patients with HIV/PTB co-infection and the viral load.
Methods: This is a prospective study of 112 HIV/PTB co-infected subjects using chest radiographs at full inspiration and the viral load.
Results: There were 112 Nigerian subjects with HIV/PTB co-infection, of which 79 (70.5%) had viral load > 10,000 copies/ml, 41(36.6%) were females, and 38(33.9%) were males. Plasma viral

**Corresponding author: E-mail: cs.nwosu@unizik.edu.ng;*

Cite as: *Olisa, U. I., Chinekwu Skye, N., Onyebuchi, N. M., Okon, I. I., & Lovelyn, O.-N. A. (2024). The Chest Radiographic Findings and the Viral Load in Adult Patients with HIV/PTB Co-Infection. Asian Journal of Medical Principles and Clinical Practice, 7(1), 268–278. Retrieved from https://journalajmpcp.com/index.php/AJMPCP/article/view/233*

load of 20-10,000 copies/ml showed 28(25%) male subjects and 14 (12.5%) female subjects. While viral load of < 20copies/ml showed females 4(3.5%) and males 1(0.9%). For normal radiographs, 13(11%) subjects with viral load > 10,000 copies/ml were seen while none were seen in subjects with < 20 copies/ml with a p-value = 0.459. Opacities were seen in 60 (53.6%) of subjects with viral load > 10,000 copies/ml and 4 (3.6%) of subjects with viral load < 20 copies/ml with a p-value= 0.670. There was no significant relationship between the zonal distribution of opacities and the chest radiographic findings with the subjects' viral load categories.

Conclusion: The chest radiographic findings did not show any significant differences in appearance in the different viral load categories of the subjects.

Keywords: Viral load; copies/ml; subjects; HIV; PTB.

1. INTRODUCTION

Tuberculosis (TB) is an infectious bacterial disease caused by closely related gram-positive, acid and alcohol-fast bacteria known as the *Mycobacterium tuberculosis* complex. It most commonly affects the lungs resulting in pulmonary tuberculosis [1]. The human immunodeficiency virus (HIV) infection continues to modify the radiographic pattern of pulmonary tuberculosis (PTB). Various strains, new mutants, and super-infection patterns of HIV may cause PTB to be radiographically present in unusual and undocumented ways. Tuberculosis is a major global health problem and one-fourth of the world's population is infected with the disease [2] . The current pattern of manifestations of PTB in the face of the ever-evolving dynamics of HIV and the increasing transmission of multi-drug resistant (MDR) pulmonary TB should be known. TB is transmitted from person to person via inhalation of droplets (aerosols) containing a critical dose of bacilli from the throat and lungs of patients with active pulmonary tuberculosis and importantly those with cavities.

Pulmonary tuberculosis is classified as primary or post-primary tuberculosis. In primary tuberculosis, radiographic signs occur around the time of inoculation. These include mediastinal lymphadenopathy, middle and lower lung involvement, and pleural effusion. Post-primary pulmonary tuberculosis is the most common type in adults. It is due to the re-activation of a latent primary infection (up to 90%) or less commonly following a repeat infection of a previously sensitized host. It usually presents with exudative inflammation. There is an initial involvement of the apical and posterior segment of the upper lobe or the superior segment of the lower lobe [3,4]. Radiographic findings are atypical in the immuno-compromised and resemble the primary type. Atypical distribution of the disease entails the involvement of the anterior segment of the upper lobe, the basal segments of the lower lobe, the right middle lobe, and the lingular segments. Other atypical patterns are diffuse lung infiltrates, mid-zone predilection, bilateral lung involvement, interstitial nodules, pleural effusion, mediastinal or hilar lymphadenopathy, and normal radiograph of the lung [5]. Human immunodeficiency virus (HIV) is a blood-borne virus; typically transmitted via sexual intercourse, shared intravenous drug paraphernalia, and mother-to-child transmission (MTCT). HIV disease is caused by infection with HIV 1 or HIV 2 which are retroviruses [6]. Patients may present with the signs or symptoms of any of the stages of the HIV infection which are features of the presenting infection or illness. There may be a benign asymptomatic phase, generalized lymphadenopathy, opportunistic malignancies, etc. [7].

HIV disease staging and classification systems are indispensable tools in the management and monitoring of the HIV pandemic. The two main classification systems in use are the Center for Disease Control (CDC) classification system [8,9] revised in 1993, and the WHO clinical staging for HIV/AIDS for adolescents and adults revised in 2007 [7].

The CDC categorization is based on the lowest documented CD4+ cell count and previously diagnosed HIV-related conditions. The Revised (2007) WHO clinical staging for HIV/AIDS for adults/adolescents [7] has four stages. The Revised (2007) WHO clinical staging system is more practical, especially in settings where CD4+ cell count testing may not be readily available. About one-third of the world population is infected with tuberculosis but does not currently have an active infection (latent TB) [10]. HIV infection increases the risk of TB 20-fold compared with HIV seronegative individuals in high HIV prevalence countries. In 2016, there were 2.5 million new cases of TB and 417,000 deaths from the disease in the African region.

Forty percent of HIV deaths were also due to pulmonary TB [11]. This study aims to relate the chest radiographic findings of patients with HIV/PTB co-infection to their viral load.

2. METHODS

2.1 Study Site

The study was a cross-sectional, descriptive plain chest radiographic finding in pulmonary tuberculosis in patients with HIV/AIDS. It was carried out in the Radiology Department at Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria. Institutional consent and authorization for the study were obtained from the various study centers following which ethical clearance was received from the Research and Ethics Committee of the Tertiary Centre with reference number NAUTH/CS/66/VOL.9/2016 /123. A detailed explanation of the study was given to each participant and written informed consent was obtained from each patient. All patient information and data obtained were treated with the utmost confidentiality. Patients' names were coded. The Declaration of Helsinki was observed.

The research assistants were healthcare providers in the different hospitals who freely volunteered to assist in the study. The researchers had a detailed and one-on-one explanation of the study with each one of them. They were educated on how to obtain written and informed consent and how to fill out the socio-demographic part of the questionnaire.

2.2 Sampling Technique

Using the consecutive sampling method, eligible participants were recruited until the sample size of 112 was reached. Patients were recruited into the study from the PTB/DOTS clinics of the various study centers.

2.3 Study Population

The study population were adults of 18 years and above with a laboratory diagnosis of pulmonary tuberculosis and patients with HIV/PTB co-infection who had not started HAART. Subjects less than 18 years old, HIV/PTB patients who had commenced HAART, and any patients who did not give consent were excluded from the study.

2.4 Study Design

The researchers and the research assistants administered the socio-demographic part of the data and obtained the patient's clinical history. The chest radiographs were interpreted under the supervision of a consultant radiologist. Chest radiographic findings and all other information were entered into the study datasheet.

2.5 Study Procedure

Chest radiographs were taken with the patient standing erect facing the standing bucky of an x-ray machine, arms akimbo or hugging the bucky. The chin was extended and centered on the middle of the top of the cassette. The chest was placed against the cassette. The median sagittal plane was adjusted at right angles to the middle of the cassette. The X-ray beam centered between the 5th & 6th thoracic vertebra passes through the chest in a postero-anterior direction. For an average patient, the manual method used about 60-70kV, and 10-12mAs were used for PA exposure. When the digitizer was used, about 60-70kV and 12-16 mAs were used. A film focus distance of 120cm was used. All exposures were taken at full arrested inspiration.

Laboratory diagnosis of PTB was done using the National TB guidelines [12]. Tests were carried out in the laboratory facilities of the various hospitals. All suspected PTB patients had two sputum samples for Ziehl-Neelson staining and one sample for Gene Xpert analysis done. Samples were collected in sterile dry containers. The first sputum sample was collected on the spot. The second sputum sample was an early morning sputum, which was collected without brushing the mouth or drinking water. Any of these samples were used for the GeneXpert analysis.

A wooden applicator was used to transfer a portion of the smear to the slide. Blood-stained, opaque, greyish, or yellowish sputum was used if present. A thin smear of approximately 2cm x1cm area is made on the slide. The smear was allowed to dry on the slide for about 15 minutes. The slide was then fixed by passing it 3-4 times through gentle flame with the smear uppermost. The slide was stained using the Ziehl-Neelson carbolfuchsin. It was heated slowly until it steamed and maintained for 3-4 minutes by intermittent heating. The slide was then rinsed under gentle running water, decolorized for not more than 3 minutes, rinsed again with water,

counter-stained for 60 seconds, and rinsed again with water. The smear was allowed to dry and examined under the microscope [13]. A positive laboratory diagnosis of PTB was made if at least a single smear came out positive.

HIV screening was done using a serial algorithm. The first line screening was done using the Determine ELISA kit®. A second-line test using Unigold ELISA kit® when positive was regarded as confirmatory. The ELISA kit® (the start pack) was used as a tiebreaker if there were conflicting results. HIV viral load was assayed using the polymerase chain reaction (PCR) principle. COBAS® AmpliPrep machine was used for the automatic separation and processing of specimens. Cobas TaqMan analyzer was used for in-vitro nucleic acid amplification and detection. This was used for Plasma viral load detection and quantitative PCR [14,15].

2.6 Data Analysis

The data was entered and cross-checked by two independent persons. The IBM Statistical Package for Social Sciences (SPSS) Statistics version 20.0 (USA; 2015) for Windows software was used for data analysis. Frequency distribution and two-way tables were used to summarize the data. Chi-square(X^2) was used to determine the strength of the association between independent and dependent variables. Using mean and standard deviation, descriptive statistics were done for variables HIV viral load. A test of significance with a p-value of less than 0.05 was considered significant. Logistic regression was also carried out.

3. RESULTS

There were a total of 112 subjects with 59 females (53.7%) and 53 males (42.3.7%) Table 1.

Table 1. Showing the gender distribution of the subjects

S/N	Sex	Distribution (%)
1.	MALE	53 (47.3%)
2.	FEMALE	59 (52.7%)
	TOTAL	112 (100%)

The highest age-specific prevalence was seen in those aged 31-40 years and 41-50 years with values of (23.6%) each. The 81-90 years age group had the least number of subjects with 4 patients (1.6%); 1 female (0.4%) and 3 males (1.2%) Fig. 1.

Among the 112 subjects with HIV/PTB co-infection, 79 (70.5%) had viral load > 10,000 copies/ml, of which 41 (36.6%) were females and 38 (33.9%) were males. Twenty-eight (25%) had plasma viral load between 20-10,000 copies/ml, out of which males and females were 14 (12.5%) respectively. Only 5 subjects (4.4%) had plasma viral load < 20 copies/ml, 4 (3.5%) females and 1 (0.9%) male Table 2.



Fig. 1. Bar chart showing the distribution of age ranges in males and females in the study population

Table 2. Plasma viral load classification among male and female patients with TB/HIV co-infection (Non-normal distribution)

Viral load classification	Gender		Total
	Male (N=53)	Female (N=59)	
<20 copies/ml	1 (0.9)	4 (3.5)	5 (4.4)
20-10,000 copies/ml	14 (12.5)	14 (12.5)	28 (25)
>10,000 copies/ml	38 (33.9)	41 (36.6)	79 (70.5)
Total	53 (47.3)	59 (52.7)	112 (100)

Table 3. Chi-square analysis showing the relationship between types of pulmonary opacities and their zonal distributions and plasma viral load in patients with HIV/PTB co-infection

CXR findings	Total Freq (%) (n=112)	Viral load classification			χ^2 value	P-value
		<20 copies/ml	20-10,000 copies/ml	>10,000 copies/ml		
Normal	19 (17.0)	0	6 (5.4)	13 (11.6)	1.432	0.489
Opacities	83 (74.1)	4 (3.6)	19 (17.0)	60 (53.6)	0.800	0.670
Alveolar/Nodular	33 (29.5)	1 (0.9)	6 (5.4)	26 (23.2)		
Interstitial	14 (12.5)	2 (1.8)	1 (0.9)	11 (9.8)	8.071	0.225
Reticulonodular	36 (32.1)	1 (0.9)	12 (10.7)	23 (20.5)		
Right lung						
Lower zone	2 (1.8)	0	2 (1.8)	0		
Mid-zone	5 (4.5)	0	2 (1.8)	3 (2.7)		
Mid + lower zone	7 (6.2)	1 (0.9)	0	6 (5.4)		
Upper zone	15 (13.4)	1 (0.9)	3 (2.7)	11 (9.8)	13.284	0.353
U + L zones	1 (0.9)	0	0	1 (0.9)		
U + M zones	16 (14.3)	1 (0.9)	5 (4.5)	10 (8.9)		
U + M + L zones	25 (22.3)	0	5 (4.5)	20 (17.9)		
Left lung						
Lower zone	3 (2.7)	1 (0.9)	0	2 (1.8)		
Mid-zone	3 (2.7)	0	1 (0.9)	2 (1.8)		
Mid + lower zone	7 (6.3)	0	2 (1.8)	5 (4.5)		
Upper zone	16 (14.3)	1 (0.9)	6 (5.4)	9 (8.0)	12.118	0.629
U + L zones	1 (0.9)	0	0	1 (0.9)		
Upper + mid-zones	7 (6.3)	0	0	7 (6.3)		
U + M + L zones	23 (20.5)	1 (0.9)	5 (4.5)	17 (15.2)		

Table 4. Chi-square analysis showing the relationship between specific chest radiographic findings and plasma viral load classification in patients with HIV/PTB co-infection

CXR findings	Total Freq (%) (n=112)	Plasma viral load classification			χ^2 value	p-value
		<20 copies/ml	20-10,000 copies/ml	>10,000 copies/ml		
Bronchopneumonia	66 (58.9)	2 (1.8)	14 (12.5)	50 (44.6)	2.283	0.319
Lobar pneumonia	17 (15.2)	2 (1.8)	5 (4.5)	10 (8.9)	2.938	0.176
Nodularity	55 (49.1)	1 (0.9)	12 (10.7)	42 (37.5)	2.441	0.328
Miliary	11 (9.8)	0	2 (1.8)	9 (8.0)	0.991	0.609
Cystic change	30 (26.8)	3 (2.7)	6 (5.4)	21 (18.8)	3.224	0.216
Fibrosis	23 (20.5)	3 (2.7)	5 (4.5)	15 (13.4)	4.872	0.123
Lymph Node	20 (17.9)	0	5 (4.5)	15 (13.4)	1.155	0.822
Pleural Effusion (PE)	37 (33.0)	2 (1.8)	10 (8.9)	25 (22.3)	0.269	0.818
Right PE	18 (16.1)	2 (1.8)	4 (3.6)	12 (10.7)	2.234	0.335
Left PE	22 (19.6)	0	8 (7.1)	14 (12.5)	2.821	0.262
Apical Cap	13 (11.6)	0	2 (1.8)	11 (9.8)	1.613	0.737
Volume loss	22 (19.6)	1 (0.9)	6 (5.4)	15 (13.4)	0.078	0.910

Table 5. Chi-square analysis showing the relationship of lung cavities and their zonal distribution with plasma viral load classification in patients with HIV/PTB co-infection

CXR findings	Total Freq (%)(n=112)	Plasma viral load classification			χ^2 value	p-value
		<20 copies/ml	20-10,000 copies/ml	>10,000 copies/ml		
Cavities	10 (8.9)	1 (0.9)	0	9 (8.0)	4.088	0.090
Thick-walled	5 (4.5)	1 (0.9)	0	4 (3.6)	4.204	0.138
Thin-walled	4 (3.6)	0	0	4 (3.6)	1.732	0.643
Right Lung						
Mid-zone	1 (0.9)	0	0	1 (0.9)	4.291	0.258
Upper zone	6 (5.4)	1 (0.9)	0	5 (4.5)		
Left Lung						
Mid-zone	1 (0.9)	0	0	1 (0.9)	1.732	0.733
Upper zone	3 (2.7)	0	0	3 (2.7)		
Number of Cavities						
One	6 (5.4)	1 (0.9)	0	5 (4.5)		
Two	2 (1.8)	0	0	2 (1.8)	0.562	1.000
Three	1 (0.9)	0	0	1 (0.9)		

Table 6. Chi-square analysis showing the relationship between post-primary PTB pattern and plasma viral load in HIV/PTB co-infected patients

Post-primary TB pattern	Total Frequency (%) (n=112)		Plasma Viral load (% Frequency)		χ^2value	p-value
	<20 copies/ml		20-10,000 copies/ml	>10,000 copies/ml		
Atypical	37 (33.0)	2 (1.78)	9 (8.0)	26 (23.2)		
Typical	36 (32.1)	2 (1.78)	10 (8.9)	24 (21.4)	0.818	0.928

Table 7. Bivariate Logistic regression analysis showing an association between patients with HIV/PTB co-infection and the development of significant abnormal chest radiographic findings

Findings	(HIV/PTB co-infection) *(n=112)*				
	OR	Std. Error	*P-value*	(95% CI)	
				Lower	Upper
Opacities	0.323	0.114	0.001*	0.161	0.647
Bronchopneumonia	0.550	0.149	0.028*	0.323	0.936
Cystic change	0.529	0.145	0.021*	0.308	0.907
Fibrosis	0.480	0.141	0.013*	0.269	0.854
Cavities	0.267	0.102	0.001*	0.126	0.566
Thick-walled	0.275	0.142	0.013*	0.099	0.760
Thin-walled	0.263	0.150	0.020*	0.086	0.807
Lymph Node	3.115	1.321	0.007*	1.357	7.152
Volume loss	0.308	0.090	<0.001*	0.173	0.548

Note.
For Outcome variables, absent = reference recoded as 0
For predictor variables, PTB patients only = reference, recoded as 1
OR = Odds ratio, * = significant p-value

Subjects with a viral load greater than 10,000 copies/ml showed the highest number of normal radiographs, 13 (11.6%) while none of those with a viral load less than 20 copies/ml had normal radiographs. This distribution was not significant, p-value = 0.489. Opacities were also seen more in those with viral load greater than 10,000 copies/ml, 60 (53.6%) and least in those with viral load less than 20 copies/ml, 4 subjects (3.6%). This was not statistically significant, the p-value was 0.670. There was no significant relationship between the zonal distribution of opacities and the patient viral load categories Table 3.

There was no significant relationship between all types of specific chest radiographic findings (bronchopneumonia, lobar pneumonia, nodularity, miliary, cystic changes, fibrosis, lymph nodes, pleural effusion, apical cap, or volume loss) and the viral load categories Table 4.

There was also no significance between the lung cavities and zonal distribution of the chest radiographic findings with the viral load categories of the patients Table 5.

Patients with Plasma viral load [PVL] > 1000 copies/ml were cumulatively the highest in number [50(44.6%)] with 26 (23.2%) subjects with an atypical presentation and a slightly decreased number of patients for typical presentation 24 (21.4%). There was no significant relationship between the patient viral load category and the presence of typical or atypical post-primary PTB pattern, the p-value = 0.928 Table 6.

In the logistic regression table, only lymphadenopathy had an Odd's ratio greater than 1, (OR = 3.115) with a p-value of 0.007. The rest of the findings; opacities, bronchopneumonia, cystic change, fibrosis, cavity, thick-walled cavity, thin-walled cavity, and volume loss had OR less than 1 (0.323, 0.550, 0.529, 0.480, 0.267, 0.275, 0.263, 0.308) and p-values of 0.001, 0.028, 0.021, 0.013, 0.001, 0.013, 0.020, < 0.001) respectively. HIV/PTB co-infection is, therefore, a strong risk factor for the development of lymphadenopathy Table 7.

4. DISCUSSION

The highest age-specific prevalence was in the age groups 31-40 years and 41-50 years age brackets. This is in concordance with studies by Ojiezeh et al [16] and Adetunji et al [17] with PTB being most prevalent in those aged between 25 and 40 years and 31-40 years respectively. It is also similar to that reported by Visawale et al [18] of 46-60 years. It is contrary to that reported by Ogbo et al [19] (National study) with the highest PTB burden seen in those aged 50-69 years. In the present study, the high disease burden seen in young adults could be due to improvement in case reporting, unemployment, and migration of young adults to overcrowded urban areas, which is a known risk factor for PTB. The variance between the lower age-specific prevalence of PTB in this study compared to the higher prevalence in the aforementioned by Ogbo et al, [19] may be indicative of the rising disease prevalence in young adults over decades.

Patients' viral load (PVL) values were skewed to the right in this study and it agrees with that reported by Govender et al. [20] Since a majority of patients were young adults, the PVL skewed to the right could be an indication of prompt diagnosis among the young adults with an obvious high level of infectiousness in the youths [21]. A slightly higher number of females 41 (36.6%) had PVL >10,000 than males 38 (33.9%) while both sexes had equal numbers 14 (12.5%) with PVL 20-10,000 copies.

There was also a significant weak negative correlation between $CD4^+$ count values and viral load, These findings agree with reports by Govender et al [20] and Haokip et al [22]. A negative correlation between $CD4^+$ and PVL may not always be the case since some patients with high $CD4^+$ count may have high PVL and vice versa [23]. Ballah et al [24] also concur with the findings of a negative correlation between CD4+ count and PVL as noted in the index study. The findings of more typical and atypical post-primary PTB patterns at high PVL values further buttress the aforementioned weak negative correlation between $CD4^+$ and PVL. Shah et al [25] stated that patients receiving anti-retroviral therapy {ART} with HIV/PTB co-infection show a significantly increased risk of death and decreased viral load suppression. Understanding the social stigma and clinical challenges faced by these patients could help to improve their healthcare and outcomes.

Ballah et al [24] however reported a statistically significant relationship between radiographic patterns and PVL. This is contrary to that seen in this study with the highest nodularity seen in patients with viral load > 10,000 copies/ml (41= 37.5%), with a p-value of 0.328. Visawale et al

[18] showed that 96.36% of their patients had decreased viral load which is contrary to that obtained in this study. The differences in the plasma viral load values could be explained by the differing methodology. Visawale et al [18] observed their patients for 6 months and reported a fall in the viral load after 6 months. Xin et al [26] reported pre-ART viral loads which were higher in HIV/PTB co-infected persons when compared with their controls.

The presence of normal radiographs, all the specific radiographic findings, and their zonal distribution across the lung were predominantly more frequent in the PVL group > 10,000 copies/ml. None of these radiographic findings showed any significant relationship with the PVL category. This is due to the aforementioned non-normal or skewed distribution of plasma viral load. Decreased adherence to HIV therapy during TB treatment because of the high pill burden and side effects might also increase the viral replication resulting in high plasma viral load. HIV/ TB co-infection, potentiate one another, accelerating the deterioration of immunological functions [27].

The Odds ratio (OR) of the development of lung cavity and volume loss in HIV/PTB co-infection were the lowest compared with the rest of the findings. The matrix metalloproteases (MMP) expression is a family of zinc-dependent proteases expressed in diseased tissues that are undergoing repair and remodeling [28]. This process leads ultimately to cavity formation, alveolar destruction, and volume loss. This is because tuberculosis-induced MMP concentrations are suppressed by HIV infection [29].

5. LIMITATION

There is a possibility of an occult immunodeficiency state which could have altered the exact radiographic pattern of PTB infection. In the normal radiographs, very small abnormalities could have been missed in the hidden areas of the lung. The time interval before the conversion of the sputum to negative against the viral load was not done which would have been an indicator of the response to therapy. Data collected on the viral load was only the last viral load result which can alter the patient during the study period.

6. CONCLUSION

There was no significant relationship between chest radiographic findings and patients' plasma viral load. The study showed that patients with HIV/PTB co-infection had very high chances of developing only lymphadenopathy, unlike the rest of the other chest findings like cavities, volume loss, or effusion.

7. RECOMMENDATION

The high age-specific prevalence of pulmonary tuberculosis in the young adults in this study shows that the disease is yet to abate. This necessitates further actions on PTB prevention and control across all levels of health care, health agencies, and governments.

ETHICAL APPROVAL AND CONSENT

It was carried out in the Radiology Department at Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria. Institutional consent and authorization for the study were obtained from the various study centers following which ethical clearance was received from the Research and Ethics Committee of the Tertiary Centre with reference number NAUTH/CS/66/VOL.9/2016/ 123. A detailed explanation of the study was given to each participant and written informed consent was obtained from each patient.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Menzies D, Adjobimey M, Ruslami R, Anete T, Oumuo S, Kim H et al. Four months of rifampicin or nine months of isoniazid for latent tuberculosis in adults. N Eng J Med. 2018;379:440-453.
2. CDC. Tuberculosis: data and statistics. Atlanta, USA: CDC; 2018.
   Available:http://www.cdc.gov/tb/statistics/default.htm.
   Accessed on 29th January 2019.
3. Sia I, Wieland M. Current concepts in the management of tuberculosis. Mayo Clin Proc. 2011;86(4):348-361.
4. Affusim C, Abah V, Kesieme E.B, Anyanwu K, Salami T.A, Eifediyi R. Effect Of low CD4+ lymphocyte count on the radiographic patterns of HIV patients with pulmonary tuberculosis among Nigerians. Tuberc Res Treat. 2013;535769:4.
   DOI:10.1155/2013/535769
5. Ravi N, Nagaraj B, Singh BK, Kumar S. A study of various chest radiological

manifestations of pulmonary tuberculosis in both human immunodeficiency virus-positive and human immunodeficiency virus-negative patients in South Indian population. West Afr J Radiol. 2017;24:14-19.

6. Nicholas J, Gilroy S, Bronze M. HIV disease: practice essentials, background, pathophysiology. Medscape. [Place unknown]. [Updated Apr 07, 2016]. Available:http://www.emedscape.medscape.com/article/211316-overview Accessed on 12th December 2017.
7. MacPherson D, Gushulak BD, Baine WB, Bala S, Gubbins PO, Holtom P, et al. Population mobility, globalization, and antimicrobial resistance. Emerg Infect Dis. 2009;15(11):1727-1731.
8. Coffey S (ed.). Guide for HIV/AIDS clinical care. Califonia: AETC National Resource Center. 2014. Available:http://www.aidsetc.org/guide/hiv-classification-cdc-and-who-staging. Accessed on 15th January 2018.
9. Weinberg JL, Kovarik CL. The WHO Clinical Staging for HIV/AIDS. AMA Ethics. 2010;12(3); 202-206.
10. WHO. Tuberculosis fact sheet. Geneva: World Health Organization; 2016. Available:http://www.who.int/mediacentre/factsheets/fs10(4/en/. Accessed on 14th November 2017.
11. WHO Africa. Tuberculosis. Brazzaville, Congo: WHO Africa; 2016. Available:http://www.afro.who.int/health-topics/tuberculosis-tb Accessed on 29th January 2019
12. World Health Organization. Xpert MTB/RIF implementation manual. Technical and operational "how-to" practical considerations. Geneva: The Bureau; 2014. Available:http://www.apps.who.int>iris Accessed on 25th January 2018.
13. Reza LW, Satyanarayna S, Enarson DA, Kumar AM, Sagili K, Kumar S et al. LED-Fluorescence Microscopy for Diagnosis of Pulmonary Tuberculosis under Pragmatic Conditions in India. PLoS ONE. 2013;8(10):e75566.
14. World Health Organization. Technical brief on HIV viral load technologies: the Bureau; 2010. Available:http://www.who.int>tech_brief_20100601-en Accessed on 25th January 2018.
15. Cobas Ampliprep/Cobas Tacman HIV test. Summary of safety and effectiveness. Available:www.fda.gov>downloads. Accessed on 28th January 2018.
16. Ojiezeh IT, Odunayo OO, Akinpelumi VA. A retrospective study on the incidence of pulmonary tuberculosis and human immunodeficiency virus co-infection among patients attending National Tuberculosis and Leprosy Control Programme, Owo Center. The Pan African Medical Journal. 2015;20:345.
17. Adetunji SO, Donbraye E, Ekong MJ, Adetunji BI. Rifampicin-resistant tuberculosis among known HIV-infected patients in Oyo State, Nigeria. J Immunoass Immunoch. 201940;40(3):289-299.
18. Visawale VC, Patil S, Joshi A. Assessment of HIV/Tb co-infection in newly diagnosed HIV positive patients and their correlation with CD4 and vViral load. Int J Res Med Sci. 2023;1:2118-23. DOI:https://dx.org/10.18203/2320-6012.ijrms.20231628
19. Ogbo FA, Ogeleka P, Okoro A, Olusanya BO, Olusanya J, Ifegwu IK et al. Tuberculosis disease burden and attributable risk factors in Nigeria, 1990-2016. Trop Med Health 2018;46:34-35.
20. Govender S, Otwombe K, Essien T, Panchia R, Mohapi L, Gray G et al. CD4 counts and viral loads of newly diagnosed HIV-infected individuals: implications for treatment as prevention. PLoS ONE 2014;9(3):e90754.
21. HIV viral load levels in young people newly linked with HIV care in the US. AIDSMAP 2014.
22. Haokip P, Singh HR, Gracy L, Marak EK and Roy A. Quantification of human immunodeficiency virus-1 viral load with CD4 cell count in antiretroviral therapy naïve patients attending Regional Institute of Medical Sciences Hospital Imphal. J Med Soc. 2018;32:98-102.
23. Shoko C, Chikobvu D. A superiority of viral load over CD4 cell count when predicting mortality in HIV patients on therapy. BMC Infectious Diseases 2019;19:(169):1-10.
24. Ballah AD, Mohammed BA, Ahmed A. Pattern and distribution of HIV associated pulmonary tuberculosis on chest radiograph in Nigeria. J Appl Med Sci. 2014;3(2):2241-2336.

25. Shah GH, Ewetola R, Etheredge G, Maluantesa L, Waterfield K, Engetele E, Kiludu A. Riak factors for Tb/HIV co-infection and Consequences for Patient Outcomes. Evidence from 241Clinics in the Democratic Republic of Congo. Int J Environ Res. Public Health. 2021;18:5165. DOI:https://doi.org/10.3390/ijerph18105165
26. Xin J, Qi T, Zou L, Tang Qi, Shen Y, Yang J ET AL. Mycobacterium Tuberculosis co-infection is associated with increased surrogate markers of the HIV reservoir. AIDS Res Ther. 2020;17:63. DOI:https://doi.org/10.1186/s12981-020-00320-0
27. Samizi FG, Panga OD, Mulugu SS, Gitige CG, Mmbaga EJ. Rate and predictors of HIV virological failure among adults on first-line anti-retroviral treatment in Dar Es Salaam, Tanzania. J Infect Dev Ctries. 2021;15:853-60. DOI:https://doi.org/10.3855/jidc.13603 PMID: 34242197.
28. Rohlwink UK, Walker NF, Ordonez AA, Li YJ, Turker EW, Elkington PT et al. Matrix metalloproteinases in pulmonary and central nervous system tuberculosis – A review. Int J Mol Sci. 2019;20(6):1350-1352.
29. Walker NF, Clark OC, Oni T, Andreu N, Tezera L, Singh S et al. Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteases. Am J Respir Crit Care Med 2012;185(9):989-997.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/117298